tailieunhanh - Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: A real-world study

Pegylated liposomal doxorubicin (PLD) is an improved formulation of doxorubicin with comparable effectiveness but significantly lower cardiotoxicity than conventional anthracycline. This study aimed to evaluate the real-world effectiveness and safety of PLD versus epirubicin as neoadjuvant or adjuvant treatment for breast cancer. | Zhang et al. BMC Cancer 2021 21 1301 https s12885-021-09050-6 RESEARCH Open Access Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer a real-world study Jin Zhang1 Hongchuan Jiang2 Jian Zhang3 Guoqiang Bao4 Guoqiang Zhang5 Haibo Wang6 and Xi Wang7 Abstract Background Pegylated liposomal doxorubicin PLD is an improved formulation of doxorubicin with comparable effectiveness but significantly lower cardiotoxicity than conventional anthracycline. This study aimed to evaluate the real-world effectiveness and safety of PLD versus epirubicin as neoadjuvant or adjuvant treatment for breast cancer. Methods Clinical data of invasive breast cancer patients who received neoadjuvant or adjuvant chemotherapy with PLD or epirubicin were retrospectively collected. Propensity score matching PSM was performed to reduce the risk of selection bias. The molecular typing of these patients included Luminal A Luminal B HER2-positive and basal-like triple-negative. The primary outcome was pathological complete response pCR rate for neoadjuvant chemotherapy and 3-year disease-free survival DFS rate for adjuvant chemotherapy. Noninferiority was suggested if the lower limit of the 95 CI for the 3-year DFS rate difference was greater than 10 . The secondary outcome was adverse reactions. Results A total of 1213 patients were included neoadjuvant n 274 adjuvant n 939 . pCR ypT0 Tis ypN0 rates of patients who received neoadjuvant chemotherapy were for the PLD group and for the epirubicin group but the difference was not statistically significant P . The 3-year DFS rate of patients who received adjuvant chemotherapy was 95 CI for the PLD group and 95 CI for the epirubicin group P . Rate difference between the two groups and its 95 CI was - . The lower limit of the 95 CI was gt suggesting that PLD is not be inferior to .

• Y khoa - Dược
• BMC Cancer
• Adjuvant chemotherapy
• Breast cancer
• Neoadjuvant chemotherapy
• Pegylated liposomal doxorubicin
• Conventional anthracycline
• Cancer patient pathways
• Colorectal cancer
• Lung cancer
• Prostate cancer
• Ovarian cancer
• Cancer detection
• Ovarian cancer symptoms
• Ovarian cancer signs
• Ovarian cancer tests
• Cancer biomarkers
• Pediatric cancer
• Familial cancer predisposition
• Hereditary cancer syndrome
• Genetic cancer susceptibility
• Advanced cancer
• Biliary tract cancer
• Multimodal intervention
• Pancreatic cancer
• Physical activity
• Breast cancer screening
• Familial breast cancer
• Young breast cancer survivors
• High risk relatives
• Randomized trial
• Childhood cancer
• Childhood cancer survivor
• Thyroid cancer screening
• Secondary cancer
• Cancer screening
• Community awareness
• Cancer education
• Cervical cancer
• Prior cancer
• Cancer survivors
• Cancer registry
• Second cancer
• Surgical oncology
• Cancer imaging
• Radiation oncologists
• Medical oncologists
• Oesophagogastric cancer
• Liver cancer
• Hepatobiliary cancer
• Multidisciplinary rehabilitation
• EGFR mutation
• Family history of cancer
• Inherited susceptibility
• Cancer predisposition genes
• Lung cancer aetiology
• Cancer stem cells
• Oct4 overexpressing lung cancer
• Human lung cancer xenograft model
• Disease free survivals
• Cancer hallmarks
• Cancer genesis
• Defiant disease
• Mutational signature
• Cancer diagnosis
• Cancer genomics
• Molecular medicine
• Whole genome sequencing
• Cancer susceptibility gene
• Breast cancer prognosis
• Next generation sequencing
• Quality of care
• Quality indicators
• Shifting cancer care
• German cancer society
• Colorectal cancer screening
• Stomach cancer screening
• Lung cancer survivor
• Physician recommendation
• Total number of lymph nodes
• Lymph node ratio
• Left colon cancer
• Right colon cancer
• Overall survival
• Cumulative incidence
• Esophageal cancer
• Head and neck cancer
• Metachronous cancer
• Young onset
• Reproductive cancer
• Risk factor
• Early detection of cancer
• Gastric cancer incidence
• Population based specialized registry
• Gastric cancer survival
• Gastric cancer clinical characteristics
• Gastric cancer pathological characteristics
• Lung Cancer Screening
• Racial disparities
• Lung Cancer diagnosis
• Screening adherence
• Second primary colorectal cancer
• Standardized incidence ratio
• Left sided colon cancer
• Right sided colon cancer
• Quality of cancer care
• Population based study